Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL)

Ricardo Parrondo, MD, Muhamad Alhaj Moustafa, MD, Craig B. Reeder, MD, Taimur Sher, MD, Vivek Roy, MD, Rahma M Warsame, MD, Victoria R. Alegria, Wilson I Gonsalves, MD, Prashant Kapoor, MD, David Dingli, MD PhD, Suzanne R. Hayman, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-139559

Published: 2020

Journal Articles

CD68+ Tumor Associated Macrophages Have Significant Impact on Therapeutic Outcome in Newly Diagnosed Multiple Myeloma (MM)

Ricardo Parrondo, MD, Muhamad Alhaj Moustafa, MD, Han W. Tun, MD, Liuyan Jiang, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-139835

Published: 2020

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Mays F Abdulazeez, MBBS, Vivek Roy, MD, Taimur Sher, MD, Victoria R. Alegria, Rahma M Warsame, MD, Jeremy Larsen, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, Prashant Kapoor, MD, Rafael Fonseca, MD, Francis K. Buadi, MB, CHB, David Dingli, MD PhD, Suzanne R. Hayman, MD, Craig B. Reeder, MD, Arshi Agrawal, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-139929

Published: 2020

Journal Articles

Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Gregory Wiseman, MD, Jennifer Peterson, MD, Thomas E. Witzig, MD, Han W. Tun, MD

Blood (2019) 134 (Supplement_1): 2809.

https://doi.org/10.1182/blood-2019-129391

Published: 2019

Journal Articles

Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Gregory Wiseman, MD, Jennifer Peterson, MD, Thomas E. Witzig, MD, Han W. Tun, MD

Blood (2019) 134 (Supplement_1): 1544.

https://doi.org/10.1182/blood-2019-130384

Published: 2019

Journal Articles

Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Victoria R. Alegria, Salman Ahmed, MD, Betsy Laplant, MS, Alak Manna, PhD, Ricardo Parrondo, MD, Vivek Roy, MD, Taimur Sher, MD, Brett Edwards, Stephanie Lanier, Keisha Jackson, Asher A. Chanan-Khan, MD, Aneel Paulus, MD

Blood (2019) 134 (Supplement_1): 3137.

https://doi.org/10.1182/blood-2019-128610

Published: 2019

Journal Articles

Carfilzomib Cardiovascular Disease: Use of the Atherosclerotic Cardiovascular Disease Score to Predict Cardiovascular Events in Multiple Myeloma Patients Treated with Carfilzomib

Ricardo Parrondo, MD, Tracy Andrews, MSc, Rima M Panchal, MD, Sejal Kothadia, MD, Camille Johnson, MD, Jieqi Liu, Giselle Alexandra Suero-Abreu, MD PhD, David H. Vesole, MD PhD, David S Siegel, MD PhD, Noa Biran, MD

Blood (2018) 132 (Supplement 1): 3254.

https://doi.org/10.1182/blood-2018-99-113722

Published: 2018

Journal Articles

Antibiotic Overload: Antibiotic Stewardship in Febrile Patients with Hematologic Malignancies

Ricardo Parrondo, MD, Veronica Mariotti, MD, Camille Johnson, MD, Faiz Afridi, MD, Tracy Andrews, PhD, Lori A. Leslie, MD

Blood (2017) 130 (Supplement 1): 3402.

https://doi.org/10.1182/blood.V130.Suppl_1.3402.3402

Published: 2017

Journal Articles

Interim or End of Treatment FGD-PET Complete Response Does Not Have Adequate Predictive Value in Mature T/NK Cell Lymphoma

Tatyana Feldman, MD, Larysa Sanchez, MD, Patrick Toth, MD, David Panush, MD, Lori A Leslie, MD, Alan P Skarbnik, MD, Anthony R. Mato, MD, Kar Fai Chow, MD, Ricardo Parrondo, MD, Veronica Mariotti, MD, Sejal Kothadia, MD, Zhen Wang, MD, Miguel Gonzalez, MD, Pritish K. Bhattacharyya, MD, Xiao Yang, MD PhD, Themba Nyirenda, PhD, Ewelina Protomastro, MS, Lori A. Leslie, MD, Andre Goy, MD

Blood (2016) 128 (22): 1813.

https://doi.org/10.1182/blood.V128.22.1813.1813

Published: 2016

NARROW

Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL)

CD68+ Tumor Associated Macrophages Have Significant Impact on Therapeutic Outcome in Newly Diagnosed Multiple Myeloma (MM)

Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience

Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Carfilzomib Cardiovascular Disease: Use of the Atherosclerotic Cardiovascular Disease Score to Predict Cardiovascular Events in Multiple Myeloma Patients Treated with Carfilzomib

Antibiotic Overload: Antibiotic Stewardship in Febrile Patients with Hematologic Malignancies

Interim or End of Treatment FGD-PET Complete Response Does Not Have Adequate Predictive Value in Mature T/NK Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only